GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (LTS:0RLB) » Definitions » EV-to-EBITDA

CTI BioPharma (LTS:0RLB) EV-to-EBITDA : -22.66 (As of May. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is CTI BioPharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CTI BioPharma's enterprise value is €1,084.98 Mil. CTI BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was €-47.88 Mil. Therefore, CTI BioPharma's EV-to-EBITDA for today is -22.66.

The historical rank and industry rank for CTI BioPharma's EV-to-EBITDA or its related term are showing as below:

LTS:0RLB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.78   Med: -2.53   Max: 0.62
Current: -23.78

During the past 13 years, the highest EV-to-EBITDA of CTI BioPharma was 0.62. The lowest was -23.78. And the median was -2.53.

LTS:0RLB's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.67 vs LTS:0RLB: -23.78

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), CTI BioPharma's stock price is €2.78781. CTI BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was €-0.555. Therefore, CTI BioPharma's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


CTI BioPharma EV-to-EBITDA Historical Data

The historical data trend for CTI BioPharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma EV-to-EBITDA Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 -1.70 -3.90 -2.44 -9.83

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.72 -5.67 -7.07 -9.83 -10.88

Competitive Comparison of CTI BioPharma's EV-to-EBITDA

For the Biotechnology subindustry, CTI BioPharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTI BioPharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's EV-to-EBITDA falls into.



CTI BioPharma EV-to-EBITDA Calculation

CTI BioPharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1084.983/-47.876
=-22.66

CTI BioPharma's current Enterprise Value is €1,084.98 Mil.
CTI BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-47.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CTI BioPharma  (LTS:0RLB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CTI BioPharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.78781/-0.555
=At Loss

CTI BioPharma's share price for today is €2.78781.
CTI BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.555.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


CTI BioPharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (LTS:0RLB) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (LTS:0RLB) Headlines

No Headlines